Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C72H120N20O21S3.Tc |
Molecular Weight | 1796.946 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[99Tc].CC(=NO)C(C)(C)NCCC(CCNC(=O)CCCC(=O)NCCCC[C@@H]1NC(=O)CSC[C@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N3)C(=O)NCCOCCOCCOCCNC(=O)COCC(N)=O)CCNC(C)(C)C(C)=NO
InChI
InChIKey=ORBUAXYWHYOTMA-HINGAUKESA-N
InChI=1S/C72H120N20O21S3.Tc/c1-45(91-108)71(3,4)82-26-21-47(22-27-83-72(5,6)46(2)92-109)20-25-77-58(95)19-12-18-57(94)76-23-11-10-16-50-65(103)89-54-42-115-116-43-55(90-67(105)52(37-62(99)100)85-59(96)38-81-63(101)49(86-68(54)106)17-13-24-80-70(74)75)69(107)87-51(36-48-14-8-7-9-15-48)66(104)88-53(41-114-44-61(98)84-50)64(102)79-29-31-111-33-35-112-34-32-110-30-28-78-60(97)40-113-39-56(73)93;/h7-9,14-15,47,49-55,82-83,108-109H,10-13,16-44H2,1-6H3,(H2,73,93)(H,76,94)(H,77,95)(H,78,97)(H,79,102)(H,81,101)(H,84,98)(H,85,96)(H,86,106)(H,87,107)(H,88,104)(H,89,103)(H,90,105)(H,99,100)(H4,74,75,80);/b91-45+,92-46+;/t49-,50-,51-,52-,53-,54-,55-;/m0./s1/i;1+1
Maraciclatide Tc-99m is radiolabelled with technetium 99m cyclic peptide maraciclatide (NC100692 or diamine dioxime-Lys-Cys-Arg-Gly-Asp-Cyc-Phe-Cys-polyethylene glycol). Maraciclatide Tc-99m binds vitronectin receptors (αvβ3 and αvβ5 integrins) with high affinity. Maraciclatide Tc-99m is used in single-photon emission computed tomography (SPECT) imaging of vitronectin receptors that are upregulated and expressed preferentially on proliferating endothelial cells. Maraciclatide Tc-99m is being developed as a diagnostic agent to determine neoplasia and cardiovascular diseases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907598 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18355693 |
0.5 nM [Kd] | ||
Target ID: CHEMBL2096675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18355693 |
0.1 nM [Kd] |
PubMed
Title | Date | PubMed |
---|---|---|
Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. | 2005 Jun 21 |
|
Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. | 2006 Sep |
|
99mTc-NC100692--a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation. | 2008 Apr |
|
αVβ3 integrin-targeted microSPECT/CT imaging of inflamed atherosclerotic plaques in mice. | 2016 Dec |
|
Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. | 2017 Dec |
|
Imaging α(v)β(3) integrin expression in skeletal metastases with (99m)Tc-maraciclatide single-photon emission computed tomography: detection and therapy response assessment. | 2018 Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16954550
Maraciclatide Tc-99m (99mTc-NC100692) was administered as a single bolus injection (with an NC100692 maximum content of 75 μg). The mean activity injected was 694 MBq (range, 561–747 MBq).
Route of Administration:
Intravascular
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
H0X34CV8RR
Created by
admin on Sat Dec 16 09:13:17 GMT 2023 , Edited by admin on Sat Dec 16 09:13:17 GMT 2023
|
PRIMARY | |||
|
139033082
Created by
admin on Sat Dec 16 09:13:17 GMT 2023 , Edited by admin on Sat Dec 16 09:13:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY